Literature DB >> 25997994

Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review.

Tomas Kalincik1.   

Abstract

Relapses (episodic exacerbations of neurological signs or symptoms) are a defining feature of relapsing-remitting multiple sclerosis (MS), the most prevalent MS phenotype. While their diagnostic value relates predominantly to the definition of clinically definite MS, their prognostic value is determined by their relatively high associated risk of incomplete remission resulting in residual disability. The mechanisms governing a relapse incidence are unknown, but numerous modifiers of relapse risk have been described, including demographic and clinical characteristics, many of which represent opportunities for improved disease management. Also relapse phenotypes have been associated with patient and disease characteristics and an individual predisposition to certain phenotypic presentations may imply individual neuroanatomical disease patterns. While immunomodulatory therapies and corticosteroids represent the mainstay of relapse prevention and acute management, respectively, their effect has only been partial and further search for more efficient relapse therapies is warranted. Other areas of research include pathophysiology and determinants of relapse incidence, recurrence and phenotypes, including the characteristics of the relapsing and non-relapsing multiple sclerosis variants and their responsiveness to therapies.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 25997994     DOI: 10.1159/000382130

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  33 in total

1.  Ozone, NO2 and PM10 are associated with the occurrence of multiple sclerosis relapses. Evidence from seasonal multi-pollutant analyses.

Authors:  Maxime Jeanjean; Marie-Abele Bind; Jonathan Roux; Jean-Claude Ongagna; Jérôme de Sèze; Denis Bard; Emmanuelle Leray
Journal:  Environ Res       Date:  2018-02-06       Impact factor: 6.498

2.  Regulatory B Cells Normalize CNS Myeloid Cell Content in a Mouse Model of Multiple Sclerosis and Promote Oligodendrogenesis and Remyelination.

Authors:  Andrea Pennati; Emily A Nylen; Ian D Duncan; Jacques Galipeau
Journal:  J Neurosci       Date:  2020-05-19       Impact factor: 6.167

3.  Advanced Oxidative Protein Products Role in Multiple Sclerosis: a Systematic Review and Meta-analysis.

Authors:  Patrícia Rodrigues; Guilherme Vargas Bochi; Gabriela Trevisan
Journal:  Mol Neurobiol       Date:  2021-08-15       Impact factor: 5.590

4.  System-Level Variation in Multiple Sclerosis Disease-Modifying Therapy Utilization: Findings From the Multiple Sclerosis Continuous Quality Improvement Research Collaborative.

Authors:  Laetitia A N'Dri; Dexter D Waters; Karen Walsh; Falguni Mehta; Brant J Oliver
Journal:  Perm J       Date:  2021-12-14

Review 5.  Dendritic Cell-Targeted Therapies to Treat Neurological Disorders.

Authors:  Asim Hussain; Hamza Rafeeq; Nimra Munir; Zara Jabeen; Nadia Afsheen; Khalil Ur Rehman; Muhammad Bilal; Hafiz M N Iqbal
Journal:  Mol Neurobiol       Date:  2021-11-06       Impact factor: 5.590

6.  Nitrosative stress parameters and the level of oxidized DNA bases in patients with multiple sclerosis.

Authors:  Vitalijs Borisovs; Jevgenijs Bodrenko; Jolanta Kalnina; Nikolajs Sjakste
Journal:  Metab Brain Dis       Date:  2021-08-21       Impact factor: 3.584

7.  Effect of Health Care Providers' Focused Discussion and Proactive Education About Relapse Management on Patient Reporting of Multiple Sclerosis Relapse.

Authors:  Royce W Waltrip; Nancy Mahler; Alina Ahsan; Leslie B Herbert
Journal:  Int J MS Care       Date:  2021-02-08

Review 8.  Prevalence of depression and anxiety in the different clinical forms of multiple sclerosis and associations with disability: A systematic review and meta-analysis.

Authors:  Diulle Spat Peres; Patrícia Rodrigues; Fernanda Tibolla Viero; Julia Maria Frare; Sabrina Qader Kudsi; Graziela Moro Meira; Gabriela Trevisan
Journal:  Brain Behav Immun Health       Date:  2022-07-06

9.  Genes differentially expressed by methylprednisolone in vivo in CD4 T lymphocytes from multiple sclerosis patients: potential biomarkers.

Authors:  C De Andres; M I García; H Goicoechea; M L Martínez-Ginés; J M García-Domínguez; M L Martín; F Romero-Delgado; A Benguría; M Sanjurjo; L A López-Fernández
Journal:  Pharmacogenomics J       Date:  2016-09-27       Impact factor: 3.550

10.  Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.

Authors:  Stanley Cohan; Jinender Kumar; Stella Arndorfer; Xuelian Zhu; Marko Zivkovic; Tom Tencer
Journal:  CNS Drugs       Date:  2021-04-13       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.